Quoin Pharmaceuticals Ltd. QNRX
Quoin Pharmaceuticals Ltd. (Nasdaq: QNRX) is a dermatology drug developer. Its lead program, QRX003, is in Phase 2 for Netherton Syndrome. Its next catalyst on record is QRX003: Quoin expects to complete recruitment of all 20 participants in Phase 2/3 Netherton Syndrome study CL-QRX003-004 by the end of 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: QRX003 — Quoin expects to complete recruitment of all 20 participants in Phase 2/3 Netherton Syndrome study CL-QRX003-004 by the end of 2026. (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| QRX003 (Netherton Syndrome) | Netherton Syndrome | small molecule | Phase 2 |
| QRX003 (Peeling Skin Syndrome) | Peeling Skin Syndrome | small molecule | Phase 2 |
| QRX009 (topical rapamycin) | Pachyonychia Congenita, Gorlin Syndrome, Tuberous Sclerosis Complex, vascular malformations | small molecule | Pre-clinical |
| QRX008 | scleroderma | small molecule | Pre-clinical |
Recent results and decisions
- Oct 20, 2026positive Single-patient compassionate use case report shows QRX003 improved skin from severe to clear with complete elimination of pruritus over 21 months.
After six weeks, the patient's Investigator's Global Assessment (IGA) score improved from 4 (severe) at baseline to 1 (almost clear), and itch, as measured by the Worst Itch Numeric Rating Scale (WI-NRS), was reduced from 5 to 1.
Filing - Aug 28, 2026positive Interim (first 6 pts, 12 wks, Phase 2/3 open-label baseline-controlled): primary IGA >=1-grade improvement in 4/6 (66.7%), p=0.0087 vs alpha 0.0215; no treatment-related SAEs.
Four of six (66.7%) participants achieved the target 1-grade or greater improvement across all of the treatment area in Investigator Global Assessment (IGA) from baseline at Week 12
Filing - Jul 9, 2026n/a FDA cleared the first-ever IND for QRX003 in Peeling Skin Syndrome (submitted June 2, 2026) with no safety concerns on study design or dosing duration.
Subsequent to quarter end, on July 9, 2026, the FDA cleared the IND and expressed no safety concerns regarding study design or duration of dosing.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.